JUN 1 7 2004 W

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on

JUNE 17, 2004 (Date of Deposit)

VIDV DAIDOLOMED

KIRK BAUMEISTER
(Name of applicant, assignee, or Registered Representative)

JUNE 17, 2004

(Date of Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: LEE ET AL

Serial No. : 10/727,432

Art Unit:

Filed

: DECEMBER 4, 2003

Examiner:

For

: CLONAL MYELOMA CELL LINES USEFUL FOR MANUFACTURING

PROTEINS IN CHEMICALLY DEFINED MEDIA

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

☐ In ac	cordance with §1.129(a), this Information
Disclosure Stat	ement is being filed in connection with [] the
first or 🗌 seco	nd After Final Submission, therefore:
. \square	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/CEN5008CIP/KB the fee of \$180.00 as set
	forth in §1.17(p).

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

Statement in Accordance with §1.97(e)	
(attached); or	
Please charge Deposit Account No. 10-	
0750/CEN5008CIP/KB the fee of $$180.00$ as set	
forth in §1.17(p).	
☐ In accordance with §1.97(d), this Information	
Disclosure Statement is being filed after the mailing date of	
either a Final Action under §1.113 or a Notice of Allowance	
under §1.311 but before the payment of the Issue Fee.	
Applicant(s) hereby petition(s) for consideration of this	
Information Disclosure Statement. Included are: Statement in	ì
Accordance with §1.97(e) as set forth below and the fee of	
\$180.00 as set forth in §1.17(p).	
Copies of each of the references listed on the	
attached Form PTO-1449 are enclosed herewith.	
) –
1449 are enclosed herewith EXCEPT THAT:	
In view of the voluminous nature of references	
[list as appropriate], and the likelihood that	
these references are available to the Examiner	
copies are not enclosed herewith.	•
oopios, and more chores north to the contract of the contract	
☑ If any of the foregoing publications are not	
available to the Examiner, Applicant will	
endeavor to supply copies at the Examiner's	
request.	
There are no listed references which are not in the	
English language	

The relevance of those listed references which are
not in the English language is as follows:
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN5008CIP/KB. This form is submitted in triplicate.

Respectfully submitted,

KIRK BAUMEISTER

Reg. No. 33,833 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8465 DATED: JUNE 17, 2004 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

	p-2/
Application Number	10/727,432
Filing Date	December 4, 2003
First Named Inventor	Chi Chang Lee
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 5008 CIP

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	1		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	
KAC		6274335	B1	Goeddel et al	08-14-2001		
KAC		5723441		Higley et al	03-03-1998		
KAC		6008195		Selsted	12-28-1999		
KAC		4780313		Koichiro et al	10-25-1988		
KAC		4504469		Melin et al	03-12-1985		
KAC		5199942		Gillis	04-06-1993		
				•	<u> </u>		

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant mm-dd-yyyy Applicant of Cited Document Initials figures appear KindCode5 Office³ Number⁴ No.1

Examiner Signature	KAC	/Karen A.	Canella,	Ph.D./	Date Considered	02/05/2007	
TEVALUED.	Indiana is not a second				*** A45CO 000 O	41	

t: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington,

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450...

¹ Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Application Number	10/727,432
Filing Date	December 4, 2003
First Named Inventor	Chi Chang Lee
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 5008 CIP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	l	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
Initials*	No.	publisher, city and/or country where published	
KAC		HILL, M., "Adaptive state of mammalian cells and its nonseparability suggestive of a quantum system," SCRIPTA MEDICA,	
_		2000, PAGES 211-222, Vol. 73, No. 4.	
KAC		FAULDS ET AL, "Abciximab: a review of its pharmacology and therapeutic potential in ischaemic heart disease," DRUGS, 1994, pages 583-598, Vol. 48, No. 4.	
KAC		MOUSER ET AL, "Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease," CLINICAL THERAPEUTICS, 1999, pages 932-942, Vol. 21, No. 6, USA.	
KAC		GORFIEN ET AL, "Growth of NSO cells in protein-free, chemically defined medium," LIFE TECHNOL INC., 2000, pages 682-687, Vol. 16, No. 5, USA.	
KAC		LOUIS ET AL, "Maintenance of clonotypic myeloma cells in serum-free media," BLOOD, 2000, Abstract #4940, Vol. 96, No. 11, USA	
KAC		FRESHNEY, R. IAN, "Culture of Animal Cells," A MANUAL OF BASIC TECHNIQUE, CHAPTER 7, pp. 92-3, UNIVERSITY OF GLASGOW.	
	L		
·	ļ		
· · · · · · · · · · · · · · · · · · ·			
	-		
	-		
·			_
			[
	1		Γ

Examiner	·			Date	· - · · · · · · · · · · · · · · · · · ·	
EAGINGICI	/Vamon 3 /	711-	ת אם	Date		B .
Cignoture	/Karen A. (Canella,	PD . D . /	0	1 02/05/2007	
Signature	,			Considered	1 04/03/400/	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.